Pudendal Nerve Block Techniques for Pain Control After Hemorrhoidectomy (PINPOINT)

September 7, 2026 updated by: Vinmec Healthcare System

Transgluteal Versus Transperineal Pudendal Nerve Block for Analgesia After Hemorrhoidectomy: A Randomized Superiority Trial (The PINPOINT Trial)

Hemorrhoidectomy is frequently associated with severe postoperative pain despite multimodal analgesia. Ultrasound-guided pudendal nerve block has become an effective regional analgesic technique, but it remains unknown whether blockade performed proximally at the ischial spine provides superior analgesia compared with the more distal transperineal approach.

The PINPOINT Trial is a prospective randomized assessor-blinded superiority trial comparing ultrasound-guided transgluteal (proximal) and transperineal (distal) pudendal nerve block in adults undergoing elective hemorrhoidectomy. The primary objective is to determine whether the proximal approach reduces cumulative opioid consumption during the first 48 postoperative hours. Secondary outcomes include pain intensity, opioid-related outcomes, recovery, complications, and patient-reported outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Context, rationale and hypothesis: Hemorrhoidectomy remains one of the most painful ambulatory surgical procedures, frequently associated with substantial postoperative opioid consumption despite multimodal analgesia. This persistent nociceptive burden has direct implications for delayed recovery, unplanned admissions, and opioid-related adverse events. Consequently, optimizing regional analgesic strategies is a priority within enhanced recovery pathways.

Pudendal nerve block (PNB), targeting sacral roots S2-S4, has emerged as an effective adjunct for postoperative analgesia in anorectal surgery. Randomized trials and meta-analyses consistently demonstrate reductions in pain scores and opioid requirements when PNB is incorporated into perioperative care. However, these studies encompass heterogeneous techniques, and critically, do not address whether the anatomical level of blockade influences clinical efficacy.

From a mechanistic perspective, the pudendal nerve divides into its terminal branches-the inferior rectal, perineal, and dorsal genital nerves-after traversing the region of the ischial spine and entering Alcock's canal. The inferior rectal nerve, which provides the principal sensory innervation to the anal canal and perianal region, typically branches proximally before the pudendal nerve courses distally within the pudendal canal. This anatomical arrangement suggests that distal approaches to PNB, such as the transperineal technique, may incompletely anesthetize the inferior rectal nerve due to injection beyond the point of branching or variable spread within the ischiorectal fossa.

In contrast, the posterior transgluteal approach targets the pudendal nerve at a more proximal location, near the ischial spine and sacrospinous ligament, where the nerve remains a single trunk. Ultrasound guidance at this level enables precise deposition of local anesthetic before division into terminal branches, theoretically ensuring a more consistent and comprehensive blockade, including the inferior rectal nerve. This distinction in injection level-proximal versus distal-represents a fundamental but underexplored determinant of block success.

Despite increasing adoption of ultrasound-guided regional anesthesia, there is a striking absence of randomized controlled trials directly comparing proximal (transgluteal) and distal (transperineal) approaches to PNB in the context of hemorrhoidectomy. Existing evidence is therefore insufficient to determine whether improved anatomical coverage translates into superior clinical analgesia or reduced opioid consumption.

Addressing this gap is clinically relevant for several reasons. First, inadequate blockade of the inferior rectal nerve may contribute to residual pain during defecation, a key determinant of patient dissatisfaction after hemorrhoidectomy. Second, identifying a more reliable and reproducible technique could standardize PNB within perioperative protocols. Third, demonstrating superiority of a proximal approach would support broader integration of ultrasound-guided regional techniques into opioid-sparing strategies.

The present trial is designed to test the hypothesis that a proximal, ultrasound-guided transgluteal PNB provides superior postoperative analgesia compared with a distal transperineal approach. By directly comparing these techniques in a randomized controlled setting, this study seeks to determine whether anatomical optimization of nerve blockade translates into meaningful clinical benefit.

Originality and innovative aspects: Hemorrhoidectomy remains associated with significant postoperative pain, often requiring substantial opioid consumption. Pudendal nerve block (PNB), targeting nerve roots from S2-S4, has demonstrated efficacy in reducing postoperative pain and opioid requirements. Anatomically, the pudendal nerve gives rise to the inferior rectal, perineal, and dorsal genital nerves. The effectiveness of PNB depends on the level of injection:

  • Transgluteal (proximal) approach: blockade at the level of the ischial spine before nerve branching
  • Transperineal (distal) approach: injection within or near Alcock's canal after branching The distal approach may spare the inferior rectal nerve, leading to suboptimal anorectal analgesia. In contrast, the proximal ultrasound-guided technique may provide a more complete and reliable block.

To date, no randomized controlled trial has directly compared proximal (transgluteal) and distal (transperineal) approaches to pudendal nerve block in hemorrhoidectomy, despite clear anatomical rationale suggesting differences in nerve coverage and analgesic efficacy.

Methods This study is a prospective, Randomized, Controlled, Parallel-group , Superiority trial, Assessor-blinded The protocol follows SPIRIT recommendations, and reporting will adhere to CONSORT guidelines Setting The study will be conducted at VinMec International Hospital, Can THo, Vietnam. Interventions Control Group (Standard Management): Trans perineal Group (Distal PNB) Spinal anesthesia protocol standardized; Ultrasound-guided transperineal approach ; Injection in rectoperineal/ischiorectal fossa; Bilateral; Ropivacaine 0. 5%, 8 mL per side; Oral Paracetamol 500 mg every 6 hours; Oral Celecoxib 200 mg every 12 hours ( if no contra-indication); Rescue opioids if NRS pain values >3/10 converted to MME Intervention Group: Transgluteal Group (Proximal PNB) General anesthesia protocol standardized; Ultrasound-guided posterior approach; Injection near ischial spine/sacrospinous ligament; Bilateral; Ropivacaine 0. 5%, 6 mL per side; Oral Paracetamol 500 mg every 6 hours; Oral Celecoxib 200 mg every 12 hours (if no contra-indication); Rescue opioids if NRS pain values >3/10 converted to MME

The Block Techniques:

Transperineal Approach Patient Positioning The patient is placed in the lithotomy position with slight hip abduction. Adequate exposure of the perineum is ensured under strict aseptic conditions.

Ultrasound Equipment and Probe Position A high-frequency linear transducer (10-18 MHz) is used. The probe is placed: Transversely or slightly oblique; On the perineum, lateral to the external anal sphincter; Over the ischio-rectal fossa.

Sonoanatomy Key structures to identify include: External anal sphincter (medial landmark); Ischioanal (ischiorectal) fossa (hypoechoic fat-filled space); Obturator internus muscle (lateral boundary); Internal pudendal artery (identified using color Doppler). The pudendal nerve is often not directly visualized, but lies medial to the internal pudendal artery and within or near Alcock's (pudendal) canal Needle Insertion Approach: in-plane, typically medial to lateral; Needle: 50mm echogenic needle advanced to the ischioanal fossa, adjacent to the internal pudendal artery.

Injection 8 mL of local anesthetic is injected per side. The spread should be observed within the ischioanal fossa Controlled by Color echo Doppler to prevent IV injection.

Transgluteal Approach Patient Positioning The patient is placed in the prone position (or lateral decubitus if needed). The gluteal region is exposed and prepared under sterile conditions.

Ultrasound Equipment and Probe Position A low-frequency curvilinear probe (2-5 MHz) or a high-frequency probe in lean patients may be used.

The probe is positioned transversely over the gluteal region, at the level of the ischial spine Sonoanatomy Key landmarks: Ischial spine (hyperechoic bony structure with acoustic shadow); Sacrospinous ligament; Sacrotuberous ligament; Internal pudendal artery (identified with Doppler). The pudendal nerve is located medial and posterior to the internal pudendal artery between the sacrospinous and sacrotuberous ligaments. It may appear as a small hyperechoic oval structure, although visualization is variable.

Needle Insertion Approach: in-plane, usually lateral-to-medial; Needle: 50 or 80 mm echogenic needle. The needle is advanced through the gluteal muscles, toward the ischial spine region, Into the interligamentous plane (between sacrospinous and sacrotuberous ligaments) Injection 6 mL of local anesthetic is injected per side. The spread of LA expands of the interligamentous space, circumferential spread around the pudendal artery controlled by Color echo doppler Sample Size: Assuming a mean 48h opioid consumption at 60 mg MME with a standard deviation: 30 mg and a clinically meaningful difference of 15 mg (25% reduction) with an Alpha risk : 0.05 (two-sided) and a β risk Power: 80%, the required sample is 64 patients per group. Accounting for 10% dropout the Total sample size: 140 patients (70 per group).

Analysis of the Population: Intention-to-treat (ITT) (primary analysis) and Per-protocol (sensitivity analysis) Descriptive Statistics: Continuous variables: mean ± SD or median (IQR) and Categorical variables: n (%)

Primary Outcome Analysis:

Comparison of cumulative MME at 48 h: If normally distributed → Student's t-test; If non-normal → Mann-Whitney U test Additionally: Linear regression adjusted for: Age, Sex, Surgical technique, Baseline pain Effect size: Mean difference with 95% confidence interval

Secondary Analyses :

Pain scores (repeated measures): Mixed-effects linear models ; Fixed effects: group, time, group × time interaction; Random intercept for patient

Time-to-event outcomes:

Time to first opioid: Kaplan-Meier analysis; Log-rank test; Cox proportional hazards model

Categorical outcomes:

Chi-square or Fisher's exact test; Report relative risks with 95% CI

Continuous outcomes:

t-test or Mann-Whitney depending on distribution Handling Missing Data : Multiple imputation if >5% missing; Sensitivity analyses Significance Threshold : p < 0.05 (two-sided) Randomization Randomization and Blinding : Allocation ratio: 1:1; Computer-generated random sequence with variable block sizes; Allocation concealment via secure electronic system

Blinding:

The patients are blinded; Outcome assessors: blinded; Data analysts: blinded; Performing anesthesiologist: not blinded Data Collection Methods: Pain opiates consumption and functional outcomes will be assessed at predefined time points using scales and validated questionnaires: NRS pain score at rest and during movement, .Lickert scale for patient satisfaction, consumption of rescue analgesia opiates (MME), Brief Pain Inventory and QOR 15 form. Data will be collected during follow-up visits or via structured interviews.

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Adults aged 18 years or older.
  • Scheduled for elective hemorrhoidectomy.
  • Hemorrhoidectomy performed using either the Milligan-Morgan or Ferguson technique.
  • ASA Physical Status I-III.
  • Able to understand the study procedures and provide written informed consent.
  • Able to complete postoperative pain and quality-of-recovery assessments.

Exclusion Criteria

  • Chronic opioid use exceeding 30 mg morphine milligram equivalents per day.
  • Known allergy or contraindication to local anesthetics.
  • Coagulopathy or other contraindication to peripheral nerve block.
  • Infection at the planned injection site.
  • Pregnancy.
  • Cognitive impairment preventing reliable completion of study questionnaires or pain assessments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Transgluteal pudendal nerve block
Ultrasound-guided bilateral transgluteal pudendal nerve block performed at the level of the ischial spine before pudendal nerve division.
Participants will receive bilateral ultrasound-guided posterior transgluteal pudendal nerve blocks under standardized general anesthesia. With the patient prone or in lateral decubitus, the gluteal region will be prepared aseptically. Ultrasound and color Doppler will identify the ischial spine, sacrospinous and sacrotuberous ligaments, and internal pudendal artery. An in-plane needle will be advanced into the interligamentous target plane, followed by injection of 5 mL ropivacaine 0.5% on each side. Local anesthetic spread will be assessed sonographically. Postoperative analgesia will include paracetamol and celecoxib when appropriate, with rescue opioids given for NRS pain >3/10. Opioid consumption will be converted to morphine milligram equivalents (MME) for analysis.
Active Comparator: Transperineal Pudendal Nerve Block
Ultrasound-guided bilateral transperineal pudendal nerve block performed within the ischiorectal fossa near Alcock's canal.
Participants will receive bilateral ultrasound-guided transperineal pudendal nerve blocks following standardized general anesthesia. In lithotomy position, the perineum will be prepared aseptically. A high-frequency ultrasound probe will identify the relevant anatomical structures and the internal pudendal artery using Color Doppler. An echogenic needle will be advanced under ultrasound guidance into the ischioanal/ischiorectal fossa adjacent to the internal pudendal artery. After aspiration, 8 mL of 0.5% ropivacaine will be injected on each side, with ultrasound assessment of anesthetic spread. Postoperative analgesia will consist of standardized paracetamol and celecoxib. Rescue opioids will be administered for pain >3/10 and converted to morphine milligram equivalents (MME) for analysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative post operative opioid consumption at 48 Hours (MME)
Time Frame: Post operative From the end of surgery to 48 hours after surgery
Cumulative opioid consumption from the end of surgery through 48 hours after surgery, expressed as morphine milligram equivalents (MME). All postoperative opioid analgesics administered during the observation period will be converted to MME using the prespecified opioid conversion table.
Post operative From the end of surgery to 48 hours after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
post operative pain intensity at rest
Time Frame: post operative at 2 hours, 6 hours, 12 hours, 24 hours and 48 hours after end of surgery
Pain intensity at rest measured by Visual Analogic Scale (VAS) ruller.
post operative at 2 hours, 6 hours, 12 hours, 24 hours and 48 hours after end of surgery
Post operative pain intensity during defecation
Time Frame: at the first post operative defecation and during the first 48 hours post operative observation period.
Pain Intensity during defecation using Visual Analogic Scale (VAS) ruler
at the first post operative defecation and during the first 48 hours post operative observation period.
Pain Intensity-time area under the curve over 48 hours after the end of surgery
Time Frame: from end of the surgery to 48 hours after surgery
Area under the curve of post operative VAS pain scores from end of the surgery through 48 hours.
from end of the surgery to 48 hours after surgery
cumulative post operative opioid consumption at 12 hours, 24 hours and 36 Hours
Time Frame: Post operative : at 12 hours, 24 hours and 36 Hours after the surgery
cumulative post operative opioid consumption at 12 hours, 24 hours and 36 Hours expressed as morphine miligram equivalents (MME)
Post operative : at 12 hours, 24 hours and 36 Hours after the surgery
Time to first rescue opioid administration
Time Frame: Post operative : from end of surgery through 48 hours after surgery
Time from end of surgery to the first rescue opioid administration
Post operative : from end of surgery through 48 hours after surgery
Proportion of participants who remain opioid free at 48 hours
Time Frame: post operative : From end of surgery through 48 hours after surgery
Proportion of participants who remain opioid free at 48 hours
post operative : From end of surgery through 48 hours after surgery
Quatilty of recovery assessed using the score QoR-15
Time Frame: Post operative : 24 hours and 48 hours after the end of surgery
Post operative Quatilty of recovery assessed using the score QoR-15
Post operative : 24 hours and 48 hours after the end of surgery
Adverse events (Nausea Vomiting Urinary retention)
Time Frame: Post operative : from end of surgery through 48 hours after surgery
Adverse events (Nausea Vomiting Urinary retention) from end of surgery through 48 hours after surgery
Post operative : from end of surgery through 48 hours after surgery
Block related complications
Time Frame: From block performance through 48 hours after surgery
Occurence of complications related to pudendal nerve block
From block performance through 48 hours after surgery
Length of hospital stay after surgery performed
Time Frame: duration of post operative hospitalization : From end of surgery to hospital discharge up to one week
Length of hospital stay from end of surgery to hospital discharge
duration of post operative hospitalization : From end of surgery to hospital discharge up to one week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 15, 2026

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

August 17, 2026

First Submitted That Met QC Criteria

September 7, 2026

First Posted (Actual)

September 10, 2026

Study Record Updates

Last Update Posted (Actual)

September 10, 2026

Last Update Submitted That Met QC Criteria

September 7, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PINPOINT-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Time Frame

Beginning 2 months and ending 3 years after the publication of results")

IPD Sharing Access Criteria

Gross data and statistical analysis will be shared on demand

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.